Stockreport

Edgewise Therapeutics doses first subject in HCM drug trial [Yahoo! Finance]

Edgewise Therapeutics, Inc.  (EWTX) 
PDF An oral, selective cardiac sarcomere modulator, EDG-7500 is claimed to slow down early contraction velocity and address the impaired cardiac relaxation linked to HCM. [Read more]